GEM
APGE icon

Global Endowment Management’s Apogee Therapeutics APGE Stock Holding History

Global Endowment Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$656K Hold
7,797
– – 0.07% 63
2025
Q4 		$589K Hold
7,797
– – 0.07% 73
2025
Q3 		$310K Hold
7,797
– – 0.04% 118
2025
Q2 		$339K Hold
7,797
– – 0.05% 100
2025
Q1 		$291K Hold
7,797
– – 0.04% 112
2024
Q4 		$353K Hold
7,797
– – 0.05% 130
2024
Q3 		$458K Hold
7,797
– – 0.05% 120
2024
Q2 		$307K Hold
7,797
– – 0.03% 120
2024
Q1 		$518K Buy
+7,797
New +$340K 0.05% 104

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Global Endowment Management's APGE Position: Q1 2026 in Review

Global Endowment Management held its Apogee Therapeutics (APGE) position steady in Q1 2026 at 7,797 shares worth $656K. The position accounts for 0.07% of the portfolio, ranked #63.

Global Endowment Management first reported a position in APGE in Q1 2024 and has held it in 9 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Global Endowment Management held 7,797 shares of Apogee Therapeutics worth $656K as of Q1 2026.
  • Global Endowment Management left its Apogee Therapeutics share count unchanged in Q1 2026.
  • Apogee Therapeutics made up 0.07% of Global Endowment Management's portfolio in Q1 2026, its #63 holding.
  • Global Endowment Management first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Global Endowment Management's 13F filing for Q1 2026, filed 14 May 2026.